{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:43:03Z","timestamp":1761871383085,"version":"build-2065373602"},"reference-count":32,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Tehran University of Medical Sciences","award":["30061"],"award-info":[{"award-number":["30061"]}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1016\/j.clml.2019.09.605","type":"journal-article","created":{"date-parts":[[2019,9,28]],"date-time":"2019-09-28T14:00:57Z","timestamp":1569679257000},"page":"e1-e10","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Evaluation of Molecular Response to Imatinib Mesylate Treatment in Iranian Patients With Chronic Myeloid Leukemia"],"prefix":"10.1016","volume":"20","author":[{"given":"Ladan","family":"Nekoohesh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shahrbano","family":"Rostami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohsen","family":"Nikbakht","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saeed","family":"Mohammadi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Davood","family":"Babakhani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kamran","family":"Alimoghaddam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad H.","family":"Ghahremani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bahram","family":"Chahardouli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"Suppl 4","key":"10.1016\/j.clml.2019.09.605_bib1","doi-asserted-by":"crossref","first-page":"iv41","DOI":"10.1093\/annonc\/mdx219","article-title":"Chronic myeloid leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Hochhaus","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2019.09.605_bib2","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/S0140-6736(07)61165-9","article-title":"Chronic myeloid leukaemia","volume":"370","author":"Hehlmann","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.clml.2019.09.605_bib3","doi-asserted-by":"crossref","first-page":"3758","DOI":"10.1182\/blood-2010-03-273979","article-title":"Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS)","volume":"116","author":"Hughes","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.09.605_bib4","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia","volume":"355","author":"Druker","year":"2006","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2019.09.605_bib5","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1002\/cam4.59","article-title":"Evaluation of 5-year imatinib treatment of 458 patients with CP-CML in routine clinical practice and prognostic impact of different BCR-ABL cutoff levels","volume":"2","author":"Klamov\u00e1","year":"2013","journal-title":"Cancer Med"},{"key":"10.1016\/j.clml.2019.09.605_bib6","doi-asserted-by":"crossref","first-page":"34","DOI":"10.3960\/jslrt.56.34","article-title":"Clinical features and treatment outcomes of 51 patients with chronic myeloid leukemia treated with a tyrosine kinase inhibitor at a single institution from 2002 to 2014","volume":"56","author":"Kawano","year":"2016","journal-title":"J\u00a0Clin Exp Hematop"},{"key":"10.1016\/j.clml.2019.09.605_bib7","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","article-title":"European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013","volume":"122","author":"Baccarani","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.09.605_bib8","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s11899-017-0375-0","article-title":"The role of early molecular response in the management of chronic phase CML","volume":"12","author":"Harrington","year":"2017","journal-title":"Curr Hematol Malig Rep"},{"key":"10.1016\/j.clml.2019.09.605_bib9","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1182\/blood-2006-01-0092","article-title":"Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results","volume":"108","author":"Hughes","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.09.605_bib10","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1177\/2040620712468289","article-title":"Management of imatinib-resistant patients with chronic myeloid leukemia","volume":"4","author":"Bhamidipati","year":"2013","journal-title":"Ther Adv Hematol"},{"key":"10.1016\/j.clml.2019.09.605_bib11","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1038\/leu.2016.5","article-title":"Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial","volume":"30","author":"Hochhaus","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2019.09.605_bib12","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1002\/cncr.26391","article-title":"Suboptimal responses in chronic myeloid leukemia","volume":"118","author":"Jabbour","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2019.09.605_bib13","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.clml.2013.03.018","article-title":"Resistance to tyrosine kinase inhibition therapy for chronic myelogenous leukemia: a clinical perspective and emerging treatment options","volume":"13","author":"Jabbour","year":"2013","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2019.09.605_bib14","doi-asserted-by":"crossref","first-page":"4437","DOI":"10.1182\/blood-2008-06-162388","article-title":"European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor","volume":"112","author":"Marin","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.09.605_bib15","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1080\/17474086.2016.1231572","article-title":"Critical appraisal of European LeukemiaNet (ELN) 2013 recommendations for the management of chronic myeloid leukemia: is it early for a warning?","volume":"9","author":"Eskazan","year":"2016","journal-title":"Expert Rev Hematol"},{"key":"10.1016\/j.clml.2019.09.605_bib16","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s13045-018-0624-2","article-title":"Past, present, and future of Bcr-Abl inhibitors: from chemical development to clinical efficacy","volume":"11","author":"Rossari","year":"2018","journal-title":"J\u00a0Hematol Oncol"},{"key":"10.1016\/j.clml.2019.09.605_bib17","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1179\/1607845412Y.0000000050","article-title":"Evaluation of T315I mutation frequency in chronic myeloid leukemia patients after imatinib resistance","volume":"18","author":"Chahardouli","year":"2013","journal-title":"Hematology"},{"key":"10.1016\/j.clml.2019.09.605_bib18","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1182\/blood-2014-03-566323","article-title":"Prognosis for patients with CML and > 10% BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 decline","volume":"124","author":"Branford","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.09.605_bib19","doi-asserted-by":"crossref","first-page":"e0173532","DOI":"10.1371\/journal.pone.0173532","article-title":"A\u00a0BCR-ABL1 cutoff of 1.5% at 3 months, determined by the GeneXpert system, predicts an optimal response in patients with chronic myeloid leukemia","volume":"12","author":"Garc\u00eda-Guti\u00e9rrez","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.clml.2019.09.605_bib20","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1159\/000343384","article-title":"Complete clearance of Ph+ metaphases after 3 months is a very early indicator of good response to imatinib as front-line treatment in chronic myelogenous leukemia","volume":"129","author":"Latagliata","year":"2013","journal-title":"Acta Haematol"},{"key":"10.1016\/j.clml.2019.09.605_bib21","doi-asserted-by":"crossref","first-page":"125","DOI":"10.3904\/kjim.2015.187","article-title":"BCR-ABL1 transcripts (MR4.5) at post-transplant 3 months as an early predictor for long-term outcomes in chronic myeloid leukemia","volume":"32","author":"Lee","year":"2017","journal-title":"Korean J Int Med"},{"key":"10.1016\/j.clml.2019.09.605_bib22","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1200\/JCO.2011.38.6565","article-title":"Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors","volume":"30","author":"Marin","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2019.09.605_bib23","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.1182\/blood-2012-11-466037","article-title":"Combining BCR-ABL1 transcript levels at 3 and 6 months in chronic myeloid leukemia: implications for early intervention strategies","volume":"121","author":"Neelakantan","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.09.605_bib24","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1038\/leu.2012.85","article-title":"Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML)","volume":"26","author":"Hanfstein","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2019.09.605_bib25","doi-asserted-by":"crossref","first-page":"150","DOI":"10.11622\/smedj.2016063","article-title":"The predictive value of early molecular response in chronic myeloid leukaemia patients treated with imatinib in a single real-world medical centre in a developing country","volume":"58","author":"Bee","year":"2017","journal-title":"Singapore Med J"},{"key":"10.1016\/j.clml.2019.09.605_bib26","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1111\/bjh.12187","article-title":"BCR-ABL1 transcript at 3 months predicts long-term outcomes following second generation tyrosine kinase inhibitor therapy in the patients with chronic myeloid leukaemia in chronic phase who failed Imatinib","volume":"160","author":"Kim","year":"2013","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2019.09.605_bib27","doi-asserted-by":"crossref","first-page":"4323","DOI":"10.1200\/JCO.2011.40.5217","article-title":"Initial molecular response at 3 months may predict both response and event-free survival at 24 months in imatinib-resistant or-intolerant patients with Philadelphia chromosome\u2013positive chronic myeloid leukemia in chronic phase treated with nilotinib","volume":"30","author":"Branford","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2019.09.605_bib28","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1179\/1607845413Y.0000000095","article-title":"Detection of BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia on imatinib","volume":"18","author":"Chahardouli","year":"2013","journal-title":"Hematology"},{"issue":"Suppl 2","key":"10.1016\/j.clml.2019.09.605_bib29","doi-asserted-by":"crossref","first-page":"S141","DOI":"10.1007\/s00277-015-2322-2","article-title":"A\u00a0review of the European LeukemiaNet recommendations for the management of CML","volume":"94","author":"Baccarani","year":"2015","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clml.2019.09.605_bib30","doi-asserted-by":"crossref","first-page":"e0171041","DOI":"10.1371\/journal.pone.0171041","article-title":"Early BCR-ABL1 transcript decline after 1 month of tyrosine kinase inhibitor therapy as an indicator for treatment response in chronic myeloid leukemia","volume":"12","author":"El Missiry","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.clml.2019.09.605_bib31","doi-asserted-by":"crossref","first-page":"E184","DOI":"10.1002\/ajh.23804","article-title":"First-line treatment of 102 chronic myeloid leukemia patients with imatinib: a long-term single institution analysis","volume":"89","author":"Vigan\u00f2","year":"2014","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2019.09.605_bib32","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.bjhh.2017.04.007","article-title":"Molecular response to imatinib mesylate of Brazilian patients with chronic myeloid leukemia","volume":"39","author":"Vieira-Mion","year":"2017","journal-title":"Rev Bras Hematol Hemoter"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265019319925?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265019319925?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:33:44Z","timestamp":1761870824000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265019319925"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["S2152265019319925"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2019.09.605","relation":{},"ISSN":["2152-2650"],"issn-type":[{"type":"print","value":"2152-2650"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluation of Molecular Response to Imatinib Mesylate Treatment in Iranian Patients With Chronic Myeloid Leukemia","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2019.09.605","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}